Divarasib in the Evolving Landscape of KRAS G12C Inhibitors for NSCLC

0
81
Kristen Rat Sarcoma viral oncogene (KRAS) mutations are one of the most common oncogenic drivers found in 12–14% of NSCLC and 4% of colorectal cancer tumors.
[Targeted Oncology]
Full Article